Effectiveness of Recovery Protocols Combination in Soccer Players

April 18, 2021 updated by: University of Vic - Central University of Catalonia

Evaluation of the Effectiveness of the Combination of Different Post-effort Recovery Methods on Quality and Recovery Time in Semi-professional Soccer Players

The main objective of this project is to compare the effectiveness of combining different recovery methods on perceptual and physical performance on soccer players.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

A crossover study will be performed and players will be assigned to different recovery methods combinations after their participation in a football game. The investigators will take baseline measures before the game and post-competition measures 24 hours after the game (one hour before the recovery intervention). Moreover, another two measure moments will be used, 24 and 48 hours after the recovery intervention.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Vic, Spain, 08500
        • Universitat de Vic-Universitat Central de Catalunya

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • semi-professional soccer players
  • 75 minutes game participation (minimum)
  • 5 years of experience practicing soccer

Exclusion Criteria:

  • goalkeepers
  • injured players

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Protocol I: Foam Roller (FR) + Cold-Water Immersion (CWI)
Foam Roller (FR) Cold-Water Immersion (CWI)
Other: Foam Roller (FR)
Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
Other: Cold-Water Immersion (CWI)
Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
Experimental: Protocol II: Stretching (STR) + Cold-Water Immersion (CWI)
Stretching (STR) Cold-Water Immersion (CWI)
Other: Cold-Water Immersion (CWI)
Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
Other: Stretching (STR)
Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
Experimental: Protocol III: Foam Roller (FR) + Stretching (STR)
Foam Roller (FR) Stretching (STR)
Other: Foam Roller (FR)
Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
Other: Stretching (STR)
Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.
Experimental: Protocol IV: Foam Roller (FR) + Stretching (STR) + Cold-Water Immersion (CWI)
Foam Roller (FR) Stretching (STR) Cold-Water Immersion (CWI)
Other: Foam Roller (FR)
Foam Roller (FR): participants will follow the Foam Roller protocol using a polyvinylchloride pipe roller (10.3-cm diameter, 0.3-cm thickness surrounded by a 1,5-cm thickness neoprene foam). They will begin with the Foam Roller at the most proximal portion of the muscle and to roll as much body mass as tolerable back and forth along it as smoothly as possible at a cadence of 1 second superior and 1 second inferior as determined with the metronome. Foam Roller will be performed for 45 seconds followed by a 15-second rest for each muscle group (quadriceps, adductors, hamstrings, abductors and calf) in each extremity and repeated once.
Other: Cold-Water Immersion (CWI)
Cold-Water Immersion (CWI): will be the last strategy used. Participants will immerse their lower body to the level of the hips for 10 minutes in cold water (10° C).
Other: Stretching (STR)
Stretching (STR): participants will perform 8-min of static stretching, involving 3 bilateral repetitions of 30 seconds held stretches to the quadriceps, adductors, hamstrings, abductors and calf muscles.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Neuromuscular or physical performance measures change: jump height
Time Frame: Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Counter Movement Jump (CMJ) will be performed to determine the maximum height in centimeters (cm). From standing position with the hands fixed on the hips, participants will be required to bend their knees to a freely chosen angle and perform a maximal vertical jump. Participants will be instructed to keep their body vertical throughout the jump, and to land with knees fully extended. Any jump that will be perceived to deviate from the required instructions will be repeated. Players will jump 3 times as high as possible and the best attempt will be used in subsequent analysis. A 15-s passive recovery phase will be provided between jumps.
Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Neuromuscular or physical performance measures change: jump flight and contact time
Time Frame: Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Counter Movement Jump (CMJ) will be performed to determine the jump flight and contact time in milliseconds (ms). From standing position with the hands fixed on the hips, participants will be required to bend their knees to a freely chosen angle and perform a maximal vertical jump. Participants will be instructed to keep their body vertical throughout the jump, and to land with knees fully extended. Any jump that will be perceived to deviate from the required instructions will be repeated. Players will jump 3 times as high as possible and the best attempt will be used in subsequent analysis. A 15-s passive recovery phase will be provided between jumps.
Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Subjective perceptual/well-being questionnaire measures change
Time Frame: Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
The well-being questionnaire (McLean et al. 2010) will assess participants' fatigue, sleep quality, general muscle soreness, stress levels and mood on a five-point scale (scores of 1[worst outcome] to 5 [best outcome], 0.5 point increments). Overall well-being will then be determined by summing the five scores.
Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Total Quality Recovery perceived (TQRper) scale. Subjective perceptual questionnaire measures change
Time Frame: Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Players will be asked to rate their recovery using the subjective questionnaire Total Quality Recovery perceived (TQRper) scale (Kenttä & Hassmén, 1998) answering the question "how recovered you feel?" on a scale which ranges from 0 (very poorly recovered) to 10 (very well recovered) and it's used as a subjective measurement to assess the fatigue suffered by the players (Laurent et al., 2011).
Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Rate of Perceived Exertion (RPE) scale. Subjective perceptual questionnaire measures change
Time Frame: Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention
Players will be asked to rate their rate of perceived exertion using Rate of Perceived Exertion (RPE) Borg's scale answering the question "how exhausted do you feel?" on a scale which ranges from 0 (extremely well-rested) to 10 (extremely exhausted) (Casamichana et al., 2013).
Baseline, 1 hour before intervention, 24 hours after intervention, 48 hours after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Vic - Central University of Catalonia

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Albert Altarriba-Bartes, UVic-UCC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 18, 2021

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2021

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 1, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 8, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 8, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 12, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 20, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 18, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RCTREC002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fatigue

Clinical Trials on Foam Roller (FR)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings